Abeona Therapeutics' pz-cel gene therapy shows the most durable wound healing in RDEB patients. See why I rate ABEO stock a ...

VandeHei outlined how he felt mainstream outlets lost the American people’s trust in three phases, through the rise of Twitter, coverage of the coronavirus pandemic and "Defund the Police ...

MANILA, Philippines – Strong export and branded sales lifted the profit of Po family-led Century Pacific Food Inc. (CNPF) by 14 percent in 20224 to P6.3 billion, with the company expecting to ...

As the anti-Tesla campaign gains momentum and the brand suffers repeated attacks across the globe, WSJ’s Aaron Zitner looks at the fallout from President Trump and Elon Musk’s alliance.

The open-label Phase 1/2 study, called EPISOD1 (NCT06100276) is intended to… People with diabetes or high cholesterol may be less likely to develop amyotrophic lateral sclerosis (ALS) or other motor ...

Copyright 2025 The Associated Press. All Rights Reserved. Copyright 2025 The Associated Press. All Rights Reserved. Texas Rangers outfielder Adolis García (53 ...

The registration deadline for Round 2 of the Prime Minister Internship Scheme 2025 has been extended to April 15, giving students and young professionals more time to apply. The scheme offers year ...

U.S. President Donald Trump sold $2.3 billion worth of his Truth Social stock the day before his "Liberation Day" tariffs announcement on April 2, 2025. Rating: False (About this rating?) Context ...

the ENHANCE Phase 3b study, and BRIUMVI as a treatment for relapsing forms of multiple sclerosis (RMS). Additional factors that could cause our actual results to differ materially include the ...

Additionally, Johnson & Johnson announced that its drug TREMFYA has shown positive results in a Phase 3b study for psoriatic arthritis, meeting key endpoints and demonstrating the ability to slow ...

the ENHANCE Phase 3b study, and BRIUMVI as a treatment for relapsing forms of multiple sclerosis (RMS). Additional factors that could cause our actual results to differ materially include the ...

Guselkumab, an IL-23 inhibitor, is effective in reducing signs, symptoms, and structural damage in active PsA, as confirmed by the APEX study. The FDA approved guselkumab in 2020 based on DISCOVER ...